Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for its patent application covering the AVERSA™ abuse deterrent transdermal technology. This technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulants.
The AVERSA™ technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the world's first abuse-deterrent opioid patch. This product could reach annual US sales of $80 million to $200 million.
The proprietary aversive agent coating employs taste aversion and has shown resistance to removal in preliminary studies. It also features a patented immediate and extended-release profile for additional deterrence.
Nutriband Inc. (NASDAQ:NTRB) ha ricevuto un Avviso di Concessione dalla National Intellectual Property Administration della Cina (CNIPA) per la sua domanda di brevetto che copre la tecnologia transdermica deterrente all'abuso AVERSA™. Questa tecnologia incorpora agenti aversivi in cerotti transdermici per prevenire abusi, deviazioni, uso improprio e esposizione accidentale a farmaci con potenziale di abuso, inclusi oppiacei e stimolanti.
La tecnologia AVERSA™ è ora protetta da brevetti in 46 paesi, compresi mercati importanti come gli USA, l'Europa, il Giappone e la Cina. Nutriband sta collaborando con Kindeva Drug Delivery per sviluppare AVERSA Fentanyl, potenzialmente il primo cerotto oppiaceo deterrente all'abuso al mondo. Questo prodotto potrebbe raggiungere vendite annuali negli USA di $80 milioni a $200 milioni.
Il rivestimento dell'agente aversivo proprietario impiega avversione al gusto e ha mostrato resistenza alla rimozione in studi preliminari. Presenta anche un profilo di rilascio immediato e prolungato brevettato per un ulteriore deterrente.
Nutriband Inc. (NASDAQ:NTRB) ha recibido un Aviso de Aprobación de la Administración Nacional de Propiedad Intelectual de China (CNIPA) para su solicitud de patente que cubre la tecnología transdérmica disuasoria al abuso AVERSA™. Esta tecnología incorpora agentes aversivos en parches transdérmicos para prevenir el abuso, la desviación, el uso indebido y la exposición accidental a medicamentos con potencial de abuso, incluidos opioides y estimulantes.
La tecnología AVERSA™ ahora está protegida por patentes en 46 países, incluidos mercados importantes como EE. UU., Europa, Japón y China. Nutriband está colaborando con Kindeva Drug Delivery para desarrollar AVERSA Fentanyl, potencialmente el primer parche de opioides disuasorio al abuso en el mundo. Este producto podría alcanzar ventas anuales en EE. UU. de $80 millones a $200 millones.
El recubrimiento del agente aversivo propietario emplea aversión al gusto y ha demostrado resistencia a la eliminación en estudios preliminares. También presenta un perfil de liberación inmediata y prolongada patentado para mayor disuasión.
Nutriband Inc. (NASDAQ:NTRB)는 중국 국가 지식 재산청(CNIPA)으로부터 AVERSA™ 남용 방지 경피 기술에 대한 특허 출원에 대해 허가 공지를 받았습니다. 이 기술은 남용, 유출, 오용 및 남용 가능성이 있는 약물에 대한 우발적인 노출을 방지하기 위해 경피 패치에 혐오성을 띤 성분을 통합합니다. 여기에는 오피오이드 및 자극제가 포함됩니다.
AVERSA™ 기술은 이제 46개국에서 특허로 보호되며, 미국, 유럽, 일본 및 중국과 같은 주요 시장이 포함됩니다. Nutriband는 Kindeva Drug Delivery와 협력하여 잠재적으로 세계 최초의 남용 방지 오피오이드 패치인 AVERSA Fentanyl을 개발하고 있습니다. 이 제품은 미국에서 연간 $80백만에서 $200백만의 판매를 올릴 수 있을 것으로 예상됩니다.
특허가 있는 혐오성 물질 코팅은 맛에 대한 혐오를 사용하며 예비 연구에서 제거에 대한 저항성을 보여주었습니다. 또한 추가적인 저항성을 위해 즉시 방출 및 장기간 방출 프로필을 갖추고 있습니다.
Nutriband Inc. (NASDAQ:NTRB) a reçu un Avis de Concession de la part de l'Administration nationale de la propriété intellectuelle de Chine (CNIPA) pour sa demande de brevet couvrant la technologie transdermique dissuasive d'abus AVERSA™. Cette technologie intègre des agents aversifs dans des patchs transdermiques pour prévenir l'abus, la déviation, l'utilisation incorrecte et l'exposition accidentelle à des médicaments ayant un potentiel d'abus, y compris les opioïdes et les stimulants.
La technologie AVERSA™ est désormais protégée par des brevets dans 46 pays, y compris des marchés majeurs tels que les États-Unis, l'Europe, le Japon et la Chine. Nutriband collabore avec Kindeva Drug Delivery pour développer AVERSA Fentanyl, potentiellement le premier patch d'opioïdes dissuasif d'abus au monde. Ce produit pourrait atteindre des ventes annuelles aux États-Unis de $80 millions à $200 millions.
Le revêtement d'agent aversif propriétaire utilise une aversion au goût et a démontré une résistance à l'élimination dans des études préliminaires. Il présente également un profil de libération immédiate et prolongée breveté pour une dissuasion supplémentaire.
Nutriband Inc. (NASDAQ:NTRB) hat von der chinesischen Nationalen Verwaltung für geistiges Eigentum (CNIPA) eine Erlaubnisbenachrichtigung für seinen Patentantrag erhalten, der die AVERSA™ Missbrauchsabwehr-Transdermaltechnologie abdeckt. Diese Technologie integriert aversive Wirkstoffe in transdermale Pflaster, um Missbrauch, Umleitung, falsche Verwendung und versehentliche Exposition gegenüber Medikamenten mit Missbrauchspotenzial, einschließlich Opioiden und Stimulanzien, zu verhindern.
Die AVERSA™ Technologie ist jetzt in 46 Ländern durch Patente geschützt, einschließlich wichtiger Märkte wie den USA, Europa, Japan und China. Nutriband arbeitet mit Kindeva Drug Delivery zusammen, um AVERSA Fentanyl zu entwickeln, möglicherweise das weltweit erste missbrauchsabwehrende Opioid-Pflaster. Dieses Produkt könnte jährliche Verkäufe in den USA von $80 Millionen bis $200 Millionen erreichen.
Die proprietäre aversive Beschichtung nutzt Geschmacksaversion und hat in vorläufigen Studien Widerstand gegen Entfernung gezeigt. Sie weist auch ein patentiertes sofortiges und verlängertes Freisetzungsprofil für zusätzlichen Abwehrschutz auf.
- Received Notice of Allowance for AVERSA™ technology patent in China
- AVERSA™ technology now protected by patents in 46 countries
- Potential annual US sales of $80-200 million for AVERSA Fentanyl
- Collaboration with Kindeva Drug Delivery for product development
- None.
Insights
The Notice of Allowance from China's CNIPA for Nutriband's AVERSA™ technology is a significant milestone. This expands their international patent portfolio to 46 countries, including major markets like the US, Europe and Japan. The broad geographical coverage strengthens Nutriband's intellectual property position and potential market reach.
AVERSA™'s abuse-deterrent transdermal technology addresses a critical need in the opioid market. By incorporating aversive agents to deter oral abuse and accidental exposure, it could significantly improve the safety profile of transdermal drugs with abuse potential. This is particularly relevant for opioids like fentanyl, where abuse and accidental exposure are serious concerns.
The partnership with Kindeva Drug Delivery for AVERSA Fentanyl development is noteworthy. If successful, it could become the world's first abuse-deterrent opioid patch, potentially capturing a significant market share. The projected annual US sales of
This patent allowance strengthens Nutriband's competitive position in the transdermal drug delivery market, particularly for abuse-deterrent formulations. The global transdermal drug delivery market is projected to grow significantly, driven by increasing prevalence of chronic diseases and demand for non-invasive drug administration.
AVERSA™ technology addresses key market needs:
- Improved safety for patients and caregivers
- Reduced potential for drug diversion and abuse
- Maintained efficacy for patients who need these medications
The potential
However, investors should consider potential challenges:
- Regulatory hurdles in proving abuse deterrence
- Competition from other abuse-deterrent formulations
- Market acceptance and adoption by healthcare providers
Overall, this patent allowance is a positive development that enhances Nutriband's long-term growth prospects in a high-potential market segment.
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology
Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch
ORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology.
The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China.
Nutriband's AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. Preliminary studies have shown that the coating is very difficult to scrape off and the technology has a patented immediate and extended-release profile which presents an additional layer of deterrence to prevent the aversive layer from easily being washed off in an attempt to separate the drug from the aversive agents.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA™ Fentanyl, which incorporates Nutriband's AVERSA™ abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach annual US sales of
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Investor Relations
RedChip Companies, Inc.
Dave Gentry
Email: NTRB@Redchip.com
Phone: 1-800-RED-CHIP (733-2447)
or 407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband, Inc.
View the original press release on accesswire.com
FAQ
What is the AVERSA™ technology developed by Nutriband (NTRB)?
In how many countries does Nutriband (NTRB) have patents for its AVERSA™ technology?
What is the potential market value for Nutriband's (NTRB) AVERSA Fentanyl product?
Who is Nutriband (NTRB) partnering with to develop AVERSA Fentanyl?
